HAEM5:Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes: Difference between revisions
| [pending revision] | [pending revision] |
| Line 38: | Line 38: | ||
|+ | |+ | ||
|WHO Essential Criteria (Genetics)* | |WHO Essential Criteria (Genetics)* | ||
|Detection of a tyrosine kinase fusion gene not classified under specific unique entities (''PDGFRA, PDGFRB, FGFR1, JAK2, FLT3, ETV6::ABL1'') | |Detection of a tyrosine kinase fusion gene not classified under specific unique entities (''PDGFRA, PDGFRB, FGFR1, JAK2, FLT3, ETV6::ABL1''). | ||
|- | |- | ||
|WHO Desirable Criteria (Genetics)* | |WHO Desirable Criteria (Genetics)* | ||
| | |Cytogenetic translocation suggesting a potential involvement of a tyrosine kinase gene, with selection of a FISH break-apart probe or another molecular assay for confirmation. | ||
|- | |- | ||
|Other Classification | |Other Classification | ||
| | |Other desirable criteria: Presence of eosinophilia. | ||
|} | |} | ||
<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>]. | <nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>]. | ||